The Science of Certainty

Rooted in the Gut-Brain-Axis, Gubra enables you to progress your preclinical development for metabolic diseases with more certainty than any other research partner. 


We offer highly specialized CRO services within the
metabolic space. 


We have longstanding experience leading large target and drug
discovery programs with external partners.

We believe 

CSR as usual is not an option

Corporate Responsibility requires more than just big ideas, it requires a firm financial commitment. Gubra is dedicated to donating 10 percent of our pretax profit to social and environmental activities every year.

Upcoming Events

Nov 4-7 American Society in Nephrology Kidney Week. Meet up with Gubra scientist Mette Viberg Østergaard.   
Nov 12-15 The Liver Meeting AASLD. Meet up with Gubra scientist director Michael Feigh. 
See all events


+ 20 September 2021 Gubra announced the signing of a research collaboration and license agreement with Bayer AG for the development of novel peptide therapeutics to treat cardiorenal diseases. Read more
+ 11 August 2021 The advancement of the first of three collaboration projects between Boehringer Ingelheim and Gubra to the clinic marks the achievement of another key milestone. Read more
See all news

Rooted in the Gut-Brain Axis

Gubra is an abbreviation for GUt and BRAin, the original key focus areas of our research and expertise. We believe that the next great leap forward in treatment paradigms within obesity, diabetes and related metabolic disorders will be found in the interplay of the gut and the brain.

A better understanding of the gut-brain axis will reveal the aetiology of diabetes, obesity and related metabolic disorders and guide us towards novel future treatments of today’s unmed medical needs.

Latest blockbuster webinars

Webinar: Browsing our Interactive Brain

In this webinar, Gubra Scientist and imaging specialist Jacob Hecksher-Sørensen introduces to our interactive brain browser Gubra 3D Explorer. With this tool, you can explore individual brain regions of interest, display quantitative c-Fos data and filter for regions with statistically significant response to drug treatment.

Play webinar

Release time and duration: May 2021, 26 minutes

Webinar: Preclinical drug discovery in NASH – Narrowing the translational gap

In this webinar Principal Scientist at Gubra Henrik Björk Hansen discusses strategies to improve clinical translatability of preclinical models of NASH. The webinar introduces a diet-induced obese and biopsy-confirmed rodent model of NASH with progressive development of fibrosis and hepatocellular carcinoma, that recapitulates the wide spectrum of the human condition. 

Play webinar

Release time and duration: February 2021, 26 minutes

Webinar: Lost in translation – how to improve the translatability of rodent models of diabetic kidney disease

Senior scientist Mette Viberg Østergaard introduces to the challenges of using current rodent models of diabetic kidney disease in drug discovery and development. Mette then presents an example of how translatability may be improved in a model of diabetic kidney disease in the setting of type 2 diabetes and hypertension.

Play webinar

Release time and duration: November 2020, 23 minutes

Webinar: Imaging diabetes using light sheet microscopy

In this webinar, principal scientist and biologist Jacob Hecksher-Sørensen talks about how to label the beta cells and image the whole pancreas, how to quantify the beta cell volume in mouse models of Type 1 and Type 2 diabetes, and lastly, Jacob takes us down new avenues imaging the nerves and vasculature.

Play webinar

Release time and duration: October 2020, 17 minutes

Do you want to be part of a great team aiming high? Join us.

Our ambition is that Gubra is a place where talented people are empowered to put their competencies and passion into play every day. We work as a team to make a difference for people with serious metabolic diseases.